These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29737795)
1. The anti-wasting effects of L-carnitine supplementation on cancer: experimental data and clinical studies. Esfahani M; Sahafi S; Derakhshandeh A; Moghaddas A Asia Pac J Clin Nutr; 2018; 27(3):503-511. PubMed ID: 29737795 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Ringseis R; Keller J; Eder K Eur J Nutr; 2013 Aug; 52(5):1421-42. PubMed ID: 23508457 [TBL] [Abstract][Full Text] [Related]
3. l-Carnitine relieves cachexia-related skeletal muscle fibrosis by inducing deltex E3 ubiquitin ligase 3L to negatively regulate the Runx2/COL1A1 axis. Lu Z; Wang L; Huo Z; Li N; Tong N; Chong F; Liu J; Zhang Y; Xu H J Cachexia Sarcopenia Muscle; 2024 Oct; 15(5):1953-1964. PubMed ID: 39091264 [TBL] [Abstract][Full Text] [Related]
4. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Busquets S; Serpe R; Toledo M; Betancourt A; Marmonti E; Orpí M; Pin F; Capdevila E; Madeddu C; López-Soriano FJ; Mantovani G; Macciò A; Argilés JM Clin Nutr; 2012 Dec; 31(6):889-95. PubMed ID: 22608917 [TBL] [Abstract][Full Text] [Related]
5. L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Liu S; Wu HJ; Zhang ZQ; Chen Q; Liu B; Wu JP; Zhu L Cancer Biol Ther; 2011 Jul; 12(2):125-30. PubMed ID: 21532335 [TBL] [Abstract][Full Text] [Related]
6. Advances in pharmacologic strategies for cancer cachexia. Madeddu C; Mantovani G; Gramignano G; Macciò A Expert Opin Pharmacother; 2015; 16(14):2163-77. PubMed ID: 26330024 [TBL] [Abstract][Full Text] [Related]
7. The role of vitamin D in cancer cachexia. Penna F; Camperi A; Muscaritoli M; Filigheddu N; Costelli P Curr Opin Support Palliat Care; 2017 Dec; 11(4):287-292. PubMed ID: 28922293 [TBL] [Abstract][Full Text] [Related]
8. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Kraft M; Kraft K; Gärtner S; Mayerle J; Simon P; Weber E; Schütte K; Stieler J; Koula-Jenik H; Holzhauer P; Gröber U; Engel G; Müller C; Feng YS; Aghdassi A; Nitsche C; Malfertheiner P; Patrzyk M; Kohlmann T; Lerch MM Nutr J; 2012 Jul; 11():52. PubMed ID: 22824168 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Mantovani G; Macciò A; Madeddu C; Gramignano G; Serpe R; Massa E; Dessì M; Tanca FM; Sanna E; Deiana L; Panzone F; Contu P; Floris C Nutrition; 2008 Apr; 24(4):305-13. PubMed ID: 18262758 [TBL] [Abstract][Full Text] [Related]
10. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111 [TBL] [Abstract][Full Text] [Related]
11. Potential protective effects of l-carnitine against neuromuscular ischemia-reperfusion injury: From experimental data to potential clinical applications. Moghaddas A; Dashti-Khavidaki S Clin Nutr; 2016 Aug; 35(4):783-90. PubMed ID: 26199084 [TBL] [Abstract][Full Text] [Related]
12. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management. Vitorino R; Moreira-Gonçalves D; Ferreira R Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794 [TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Melstrom LG; Melstrom KA; Ding XZ; Adrian TE Histol Histopathol; 2007 Jul; 22(7):805-14. PubMed ID: 17455154 [TBL] [Abstract][Full Text] [Related]
15. L-Carnitine Ameliorates Cancer Cachexia in Mice Partly via the Carnitine Palmitoyltransferase-Associated PPAR-γ Signaling Pathway. Jiang F; Zhang Z; Zhang Y; Pan X; Yu L; Liu S Oncol Res Treat; 2015; 38(10):511-6. PubMed ID: 26452216 [TBL] [Abstract][Full Text] [Related]
16. l-carnitine and cancer cachexia: Clinical and experimental aspects. Silvério R; Laviano A; Rossi Fanelli F; Seelaender M J Cachexia Sarcopenia Muscle; 2011 Mar; 2(1):37-44. PubMed ID: 21475677 [TBL] [Abstract][Full Text] [Related]
17. Novel treatments for cancer cachexia. Bossola M; Pacelli F; Doglietto GB Expert Opin Investig Drugs; 2007 Aug; 16(8):1241-53. PubMed ID: 17685872 [TBL] [Abstract][Full Text] [Related]
18. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. Szefel J; Kruszewski WJ; Ciesielski M; Szajewski M; Kawecki K; Aleksandrowicz-Wrona E; Jankun J; Lysiak-Szydłowska W Oncol Rep; 2012 Jul; 28(1):319-23. PubMed ID: 22562434 [TBL] [Abstract][Full Text] [Related]
19. Cancer cachexia: it's time for more clinical trials. Bossola M; Pacelli F; Tortorelli A; Doglietto GB Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025 [TBL] [Abstract][Full Text] [Related]
20. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. May PE; Barber A; D'Olimpio JT; Hourihane A; Abumrad NN Am J Surg; 2002 Apr; 183(4):471-9. PubMed ID: 11975938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]